

TABLE 88: LIVER TRANSPLANT RECIPIENTS

INCLUDED STUDIES ^a	ITT N	TREATMENT ARM	AGE (YEARS) MEAN (SD)/MEDIAN (RANGE)	% MALE	PREVIOUS TREATMENT EXPERIENCE				PREVIOUS RESPONSE			GENOTYPE AND SUBTYPE (%)								PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASE-LINE VIRAL LOAD, MEAN LOG ₁₀ (SD)	
					PR (%)	DAA + PR (%)	DAA ONLY (%)	MIXED	RELAPSE (%)	NULL (%)	PARTIAL (%)	1	1a	1b	2	3	4	5	6	COMBINED/OTHER	CIRRHOTIC (%)		NON-CIRRHOTIC (%)
Charlton et al., 2015	40	SOF24 + RBV24	Median 59 (range 49 to 75)	78	55	22.5	0	^b	26	35	20	83	55	28	0	15	3	0	0	40	60	6.74 (4.49 to 7.59)	83
Kwo et al., 2014 CORAL-I	34	PAR/RIT24 + OMB24 + DAS24 + RBV24	59.6 (6.6)/NR (NR)	79	NR	NR	NR		NR	71	NR		85	15						0	100	6.6 (0.5)	

DAS = dasabuvir; ITT = intention-to-treat; NR = not reported; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; RIT = ritonavir; RBV = ribavirin; SD = standard deviation; SOF = sofosbuvir.

^a Both are combined populations of treatment-naive and -experienced patients.

^b Peginterferon or interferon only: 7.5%; other plus peginterferon and ribavirin: 2.5%; naive: 12.5%.